Lung tumours reprogram pulmonary Dendritic cell immunogenicity at the microrna level

International Journal of Cancer

Volumn 135, Issue 12, 2014, Pages 2868-2877

  Pyfferoen, Lotte ^a,b,c   Mestdagh, Pieter ^a   Vergote, Karl ^b   De Cabooter, Nancy ^a   Vandesompele, Jo ^a   Lambrecht, Bart N ^b,c,d   Vermaelen, Karim Y ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cells; Dicer; Lung cancer; MicroRNAs

Indexed keywords

CYTOKINE; DEAD BOX PROTEIN; DICER1 PROTEIN, HUMAN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; MICRORNA; MIRN301 MICRORNA, MOUSE; RIBONUCLEASE III; TUMOR ANTIGEN;

ANIMAL; BONE MARROW CELL; C57BL MOUSE; CANCER TRANSPLANTATION; CELL PROLIFERATION; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENE DELETION; HELPER CELL; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; LUNG NEOPLASMS; METABOLISM; MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; BONE MARROW CELLS; CELL PROLIFERATION; CYTOKINES; DEAD-BOX RNA HELICASES; DENDRITIC CELLS; GENE DELETION; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-13; INTERLEUKIN-17; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; NEOPLASM TRANSPLANTATION; RIBONUCLEASE III; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84908680606     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28945     Document Type: Article

References (47)

1. Fuertes MB, Kacha AK, Kline J, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011;208:2005-16.
2. Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol 1996;170:101-10.
3. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107-11.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
5. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
6. Aspord C, Pedroza-Gonzalez A, Gallegos M, et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med 2007; 204:1037-47.
7. DeNardo DG, Barreto JB, Andreu P, et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16: 91-102.
8. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012;72:2162-71.
9. Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457-64.
10. Berger H, Vegran F, Chikh M, et al. SOCS3 transactivation by PPARgamma prevents IL-17- driven cancer growth. Cancer Res 2013;73:3578-90.
11. Sempere LF. Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer. Expert Rev Mol Diagn 2011; 11:813-27.
12. Olson P, Lu J, Zhang H, et al. MicroRNA dynamics in the stages of tumorigenesis correlate with hallmark capabilities of cancer. Genes Dev 2009;23:2152-65.
13. Caton ML, Smith-Raska MR, Reizis B. Notch- RBP-J signaling controls the homeostasis of CD8- dendritic cells in the spleen. J Exp Med 2007;204: 1653-64.
14. Barnden MJ, Allison J, Heath WR, et al. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998;76:34-40.
15. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010;330:827-30.
16. Naik SH, Proietto AI, Wilson NS, et al. Cutting edge: generation of splenic CD8+ and CD8- dendritic cell equivalents in Fms-like tyrosine kinase 3 ligand bone marrow cultures. J Immunol 2005; 174:6592-7.
17. Mestdagh P, Feys T, Bernard N, et al. Highthroughput stem-loop RT-qPCR miRNA expression profiling using minute amounts of input RNA. Nucleic Acids Res 2008;36:e143.
18. Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for micro- RNA RT-qPCR data normalization. Genome Biol 2009;10:R64.
19. Vermaelen KY, Carro-Muino I, Lambrecht BN, et al. Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes. J Exp Med 2001;193:51-60.
20. Willart MA, Jan de Heer H, Hammad H, et al. The lung vascular filter as a site of immuneinduction for T cell responses to large embolic antigen. J Exp Med 2009;206:2823-35.
21. Lambrecht BN, Pauwels RA, Fazekas De St Groth B. Induction of rapid T cell activation, division, and recirculation by intratracheal injection of dendritic cells in a TCR transgenic model. Journal of immunology 2000;164: 2937-46.
22. Plantinga M, Guilliams M, Vanheerswynghels M, et al. Conventional and monocyte-derived CD11b(+) dendritic cells initiate and maintain t helper 2 cell-mediated immunity to house dust mite allergen. Immunity 2013;38:322-35.
23. Provoost S, Maes T, Willart MA, et al. Diesel exhaust particles stimulate adaptive immunity by acting on pulmonary dendritic cells. J Immunol 2010;184:426-32.
24. Turley SJ, Fletcher AL, Elpek KG. The stromal and haematopoietic antigen-presenting cells that reside in secondary lymphoid organs. Nat Rev Immunol 2010;10:813-25.
25. Savai R, Wolf JC, Greschus S, et al. Analysis of tumor vessel supply in Lewis lung carcinoma in mice by fluorescent microsphere distribution and imaging with micro- and flat-panel computed tomography. Am J Pathol 2005;167:937-46.
26. Desch AN, Randolph GJ, Murphy K, et al. CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J Exp Med 2011;208:1789-97.
27. Gerner MY, Casey KA, Mescher MF. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol 2008;181:155-64.
28. Stoitzner P, Green LK, Jung JY, et al. Inefficient presentation of tumor-derived antigen by tumorinfiltrating dendritic cells. Cancer Immunol Immunother 2008;57:1665-73.
29. Curtsinger JM, Lins DC, Mescher MF. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J Exp Med 2003;197:1141-51.
30. Shi W, Gerster K, Alajez NM, et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res 2011;71:2926-37.
31. Saito M, Schetter AJ, Mollerup S, et al. The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res 2011;17:1875-82.
32. Hatley ME, Patrick DM, Garcia MR, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010;18:282-93.
33. Wong QW, Ching AK, Chan AW, et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res 2010;16:867-75.
34. Ma Y, Zhang P, Yang J, et al. Candidate micro- RNA biomarkers in human colorectal cancer: systematic review profiling studies and experimental validation. Int J Cancer 2012;130:2077-87.
35. Ichimi T, Enokida H, Okuno Y, et al. Identification of novel microRNA targets based on micro- RNA signatures in bladder cancer. Int J Cancer 2009;125:345-52.
36. Mycko MP, Cichalewska M, Machlanska A, et al. microRNA-301a regulation of a T-helper 17 immune response controls autoimmune demyelination. Proc Natl Acad Sci USA 2012;109: E1248-E1257.
37. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004;10: 48-54.
38. Lu TX, Hartner J, Lim EJ, et al. MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. J Immunol 2011;187:3362-73.
39. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010;11: 141-7.
40. Kuipers H, Schnorfeil FM, Brocker T. Differentially expressed microRNAs regulate plasmacytoid vs. conventional dendritic cell development. Mol Immunol 2010;48:333-40.
41. Holmstrom K, Pedersen AW, Claesson MH, et al. Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy. Human Immunol 2010;71:67-73.
42. Min S, Liang X, Zhang M, et al. Multiple tumorassociated microRNAs modulate the survival and longevity of dendritic cells by targeting YWHAZ and Bcl2 signaling pathways. J Immunol 2013; 190:2437-46.
43. Kumar MS, Lu J, Mercer KL, et al. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007;39: 673-7.
44. Jakubzick C, Tacke F, Llodra J, et al. Modulation of dendritic cell trafficking to and from the airways. J Immunol 2006;176: 3578-84.
45. Lambrecht BN, Peleman RA, Bullock GR, et al. Sensitization to inhaled antigen by intratracheal instillation of dendritic cells. Clin Exp Allergy 2000;30:214-24.
46. Havenith CE, van Miert PP, Breedijk AJ, et al. Migration of dendritic cells into the draining lymph nodes of the lung after intratracheal instillation. Am J Respir Cell Mol Biol 1993;9:484-8.
47. Cubillos-Ruiz JR, Baird JR, Tesone AJ, et al. Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. Cancer Res 2012;72:1683-93.